Jump Financial, LLC Mersana Therapeutics, Inc. Transaction History

Jump Financial, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.23 - $2.25 $99,091 - $181,264	-80,562 Closed	0 $0
Q2 2024 Aug 14, 2024	BUY	$2.0 - $4.45 $128,602 - $286,139	64,301 Added 395.43%	80,562 $161,000
Q1 2024 May 13, 2024	BUY	$2.16 - $5.94 $35,123 - $96,590	16,261 New	16,261 $72,000
Q2 2023 Oct 21, 2024	SELL	$3.08 - $9.55 $179,163 - $555,523	-58,170 Reduced 72.21%	22,392 $73,000
Q2 2023 Aug 07, 2023	BUY	$3.08 - $9.55 $68,967 - $213,843	22,392 New	22,392 $73,000
Q4 2022 Feb 13, 2023	BUY	$5.65 - $7.86 $113,084 - $157,317	20,015 Added 44.88%	64,613 $378,000
Q3 2022 Nov 07, 2022	BUY	$4.63 - $8.0 $206,488 - $356,784	44,598 New	44,598 $301,000
Q2 2022 Aug 09, 2022	SELL	$2.84 - $5.0 $191,700 - $337,500	-67,500 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$3.74 - $6.63 $20,196 - $35,802	-5,400 Reduced 7.41%	67,500 $269,000
Q4 2021 Feb 10, 2022	BUY	$5.48 - $9.86 $399,492 - $718,794	72,900 New	72,900 $453,000
Q2 2021 Aug 13, 2021	SELL	$13.28 - $18.07 $336,408 - $457,749	-25,332 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$15.31 - $26.52 $387,832 - $671,804	25,332 New	25,332 $409,000

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $149M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.